CRE Homepage About The CRE Advisory Board Newsletter Search Links Representation Comments/Ideas
Data Access
Data Quality
Regulation by Litigation
Regulation by Appropriation
Special Projects
CRE Watch List
OMB Papers
Abstracts and Reviews
Regulatory Review
Voluntary Standards Program
CRE Report Card
Public Docket Preparation
Consumer Response Service
Site Search

Enter keyword(s) to search

®: CRE Regulatory Action of the Week

FDA Again Extends Comment Period for Review of Homeopathic Products Regulation
The U.S. Food and Drug Administration is reconsidering its regulatory framework for homeopathic products after 25 years of regulation. The FDA is reopening the comment period for the notice of public hearing that appeared in the Federal Register of March 27, 2015. FDA is taking this action in response to requests to allow interested persons additional time to submit comments. FDA already extended this comment period once before on June 10, 2015 (80 FR 32868). The deadline for comments is now November 9, 2015.

  • Click here for FDA's Federal Register notice of this action.